SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

NEW YORK – Leapfrog Bio on Wednesday said it will move on to a Phase II trial of its bromodomain and extra-terminal domain (BET) protein inhibitor LFB-190 in lung, colon, and bladder cancer after ...

SpliceBio aims to begin a study testing its protein splicing gene therapy in the first half of 2025, now that the FDA has cleared its IND.